IMRX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	338 325
Gjennomsnittsvolum	754 996
Markedsverdi	48.63M
EPS	$-0.520 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.870
ATR14	$0.00200 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Cormorant Asset Management, Lp	Sell	100	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	300	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	100	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	600	Class A Common Stock
2024-04-01	Cormorant Asset Management, Lp	Sell	10	Class A Common Stock

INSIDER POWER
6.35
Last 92 transactions
Buy: 3 241 516 \| Sell: 1 367 921

Volum Korrelasjon

Lang: 0.25 (neutral)

Kort: -0.13 (neutral)

Signal:(53.257) Neutral

Immuneering Corporation Korrelasjon

10 Mest positive korrelasjoner
CPSH	0.958
RGF	0.956
PHCF	0.955
PAIC	0.952
WKSP	0.95
SVAC	0.945
PRTS	0.942
JRJC	0.942
TIL	0.941
BLPH	0.933

10 Mest negative korrelasjoner
NETE	-0.972
GRCL	-0.959
MMAC	-0.953
VITL	-0.951
SASR	-0.949
MNMD	-0.947
MIRO	-0.945
DXPE	-0.943
BSRR	-0.942
GIFI	-0.942

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Immuneering Corporation Korrelasjon - Valuta/Råvare

-0.29
( neutral )

-0.22
( neutral )

0.00
( neutral )

-0.68
( moderate negative )

-0.19
( neutral )

Immuneering Corporation Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-764 138 (0.00 %)
EPS:	$-1.880

FY	2023
Omsetning:	$0
Bruttogevinst:	$-764 138 (0.00 %)
EPS:	$-1.880

FY	2022
Omsetning:	$316 952
Bruttogevinst:	$158 830 (50.11 %)
EPS:	$-1.870

FY	2021
Omsetning:	$2.08M
Bruttogevinst:	$927 000 (44.57 %)
EPS:	$-2.46

Financial Reports:

No articles found.

Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.